Cori Millen, DO
Neurology · Englewood, CONPI 1245443506
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,259 of the $197,527 with a category attached, or 75.1%. 27 manufacturers reported payments, led by Amgen at 48.9% of the total. Reporting peaked in 2019 at $101,748 and has fallen 98.6% since, to $1,385 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $278.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$97K
- Lilly USA, LLC$62K
- AbbVie$19K
- Teva Pharmaceuticals USA, Inc.$11K
- Biohaven Pharmaceuticals, Inc.$5K
- Eli Lilly$2K
- plus $3K from 21 others
Across 97 payments — averaging $4647.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$268K
- Eli Lilly$160K
- Amgen$16K
- Teva Pharmaceuticals USA, Inc.$7K
What the payments were for
- Consulting fees$22,65011%
- Speaking & faculty fees$148,25975%
- Grants$880%
- Travel & lodging$15,1698%
- Food & beverage$11,1496%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 157 | $96,654 |
| Lilly USA, LLC | 171 | $61,907 |
| AbbVie(2 entities) | 201 | $18,737 |
| Teva Pharmaceuticals USA, Inc. | 56 | $10,555 |
| Biohaven Pharmaceuticals, Inc. | 6 | $5,009 |
| Eli Lilly | 4 | $2,026 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $1,193 |
| Pfizer | 28 | $320 |
| Lundbeck LLC | 19 | $283 |
| Upsher-smith Laboratories LLC | 7 | $113 |
| Scilex Pharmaceuticals Inc. | 6 | $105 |
| Biogen | 6 | $89 |
| Assertio Therapeutics, Inc. | 4 | $78 |
| Novartis | 5 | $70 |
| UCB, Inc. | 2 | $63 |
| EMD Serono, Inc. | 3 | $57 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Promius Pharma LLC | 3 | $36 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Impel Pharmaceuticals Inc. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $23 |
| Merck | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,527 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 91 | $124,905 |
| UbrelvyUbrogepant | 24 | $33,896 |
| Emgality PenGalcanezumab-Gnlm | 41 | $32,399 |
| Nurtec OdtRimegepant Sulfate | 23 | $28,834 |
| QuliptaAtogepant | 26 | $28,462 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $15,189 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $11,356 |
| Baclofen | 25 | $4,933 |
| Sumatriptan Succinate | 29 | $2,275 |
| Naratriptan Hcl | 45 | $1,316 |
| Gabapentin | 37 | $1,066 |
| RizatriptanRizatriptan Benzoate | 18 | $730 |
| Cyclobenzaprine Hcl | 21 | $647 |
| Ondansetron OdtOndansetron | 14 | $467 |
| Pregabalin | 15 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $18,737 | $187,263141 claims |
| PfizerNurtec Odt | $320 | $28,83423 claims |
| Upsher-smith Laboratories LLCTopiramate | $113 | $18925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Englewood
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Kirsten BrachtEnglewood$151K
- Aaron HaugEnglewood$57K
- Karen KarwaEnglewood$52K
- Kevin PatelEnglewood$26K
- Meagen SalinasEnglewood$24K
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.